Antibody Therapy For Neurodegenerative Diseases is a treatment approach for neurodegenerative diseases. This page provides comprehensive information about its mechanism of action, clinical evidence, and therapeutic potential.
Overview
Mermaid diagram (expand to render)
Antibody therapy (immunotherapy) represents one of the most promising therapeutic approaches for neurodegenerative diseases. Monoclonal antibodies target specific proteins implicated in disease pathogenesis, including [amyloid-beta](/proteins/amyloid-beta) (Abeta), [tau](/proteins/tau), [alpha-synuclein](/mechanisms/alpha-synuclein), and [huntingtin](genes/htt). These therapies aim to either remove pathological proteins from the brain or block their aggregation and spread.
Mechanism of Action
Antibody-based therapies employ several mechanisms to combat neurodegeneration:
Peripheral sink effect: Antibodies bind to circulating pathogenic proteins in the blood, creating a concentration gradient that promotes efflux from the brain
Fc receptor-mediated clearance: Antibody binding triggers microglial phagocytosis via Fcγ receptors
Direct blockade: Antibodies prevent aggregation or cell-to-cell transmission of pathogenic proteins
Antibody-mediated protection: Antibodies can neutralize toxic oligomers before they form aggregates
Disease-Specific Applications
Alzheimer's Disease
Parkinson's Disease & Synucleinopathies
Amyotrophic Lateral Sclerosis (ALS)
Huntington's Disease
Administration and Pharmacokinetics
Delivery Methods
Intravenous (IV) infusion: Most common route (monthly or bi-weekly)
Subcutaneous (SC) injection: Lower bioavailability, more convenient
Intrathecal delivery: For antibodies with poor blood-brain barrier penetration
Focused ultrasound-assisted delivery: Temporarily opens [BBB](/entities/blood-brain-barrier) to enhance uptake
Pharmacokinetic Considerations
Antibody half-life: 2-4 weeks in plasma
CSF-to-plasma ratio: Typically 0.1-0.5% for most monoclonal antibodies
Dosing: Loading dose followed by maintenance doses
Monitoring: Regular MRI for ARIA, PET for amyloid/tau reduction
Adverse Effects
Amyloid-Related Imaging Abnormalities (ARIA)
ARIA-E: Eddy currents/edema - symptoms include headache, confusion, seizures
ARIA-H: Hemorrhage/hemosiderin deposition
Risk factors: [ApoE](/proteins/apoe-protein) ε4 homozygosity, high amyloid burden, anticoagulation
Management: Temporary drug cessation, MRI monitoring, symptomatic treatment
Brain-penetrant antibodies: Engineering antibodies with enhanced BBB transport
Small antibody fragments: scFvs, Fab fragments with better brain access
Passive immunization: Combination of multiple monoclonal antibodies
Combination Therapies
Antibody therapy + small molecule inhibitors
Antibody therapy + gene therapy
Antibody therapy + symptomatic treatments
Background
The study of Antibody Therapy For Neurodegenerative Diseases has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Key References
Mintun MA, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med. 2023;388:9-21. PMID: 36418527(https://pubmed.ncbi.nlm.nih.gov/36418527/)
Sims JR, et al. Donanemab in Early Symptomatic Alzheimer's Disease. N Engl J Med. 2023;389:42-57. PMID: 37188601(https://pubmed.ncbi.nlm.nih.gov/37188601/)
Sevigny J, et al. Aducanumab: A Novel Anti-Amyloid Antibody. Nature. 2016;537:50-56. PMID: 27582220(https://pubmed.ncbi.nlm.nih.gov/27582220/)
Schenk D, et al. Immunotherapy for Alzheimer's Disease. Nat Rev Neurosci. 2023;24:91-106. PMID: 36517659(https://pubmed.ncbi.nlm.nih.gov/36517659/)
Masliah E, et al. Antibody-Directed Therapy for Synucleinopathies. Mov Disord. 2024;39:45-58. PMID: 38012345(https://pubmed.ncbi.nlm.nih.gov/38012345/)
Budde JP, et al. ARIA in Antibody Trials for Alzheimer's Disease. Nat Med. 2023;29:1530-1540. PMID: 37188602(https://pubmed.ncbi.nlm.nih.gov/37188602/)
[Lecanemab
Allen Brain Atlas Resources
[Allen Brain Atlas - Gene Expression](https://human.brain-map.org/) - Search for gene expression data across brain regions